Stephen John Carter
Chief Executive Officer at Malaria Research Co. Pty Ltd.
Profile
Stephen John Carter is currently the Chief Executive Officer of Malaria Research Co. Pty Ltd.
He was previously the Chief Executive Officer & Managing Director of Arovella Therapeutics Ltd.
from 2009 to 2019.
Prior to that, he was the Non-Executive Chairman of Holista CollTech Ltd.
from 2006 to 2009.
He also served as Chairman of Delmedica Ltd.
and Director of Solbec Pharmaceuticals Ltd.
Stephen John Carter active positions
| Companies | Position | Start |
|---|---|---|
Malaria Research Co. Pty Ltd.
 Malaria Research Co. Pty Ltd. BiotechnologyHealth Technology Malaria Research Co. Pty Ltd. develops pharmaceuticals segment for the treatment of malaria. Its product includes ArtiMist, sublingual anti-malarial spray for the treatment of Plasmodium falciparum pediatric malaria. The company is headquartered in Osborne Park, Australia. | Chief Executive Officer | - |
Former positions of Stephen John Carter
| Companies | Position | End |
|---|---|---|
| AROVELLA THERAPEUTICS LIMITED | Chief Executive Officer | 22/09/2019 |
| HOLISTA COLLTECH LIMITED | Chairman | 10/11/2009 |
| Solbec Pharmaceuticals Ltd. | Director/Board Member | 25/09/2006 |
| Delmedica Ltd. | Chairman | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AROVELLA THERAPEUTICS LIMITED | Health Technology |
| HOLISTA COLLTECH LIMITED | Health Technology |
| Private companies | 3 |
|---|---|
| Solbec Pharmaceuticals Ltd. | Health Technology |
Malaria Research Co. Pty Ltd.
Malaria Research Co. Pty Ltd. BiotechnologyHealth Technology Malaria Research Co. Pty Ltd. develops pharmaceuticals segment for the treatment of malaria. Its product includes ArtiMist, sublingual anti-malarial spray for the treatment of Plasmodium falciparum pediatric malaria. The company is headquartered in Osborne Park, Australia. | Health Technology |
| Delmedica Ltd. |
- Stock Market
- Insiders
- Stephen John Carter
